BASECAMP RESEARCH RAISES $140M TO BUILD AI FROM BIOLOGY

Basecamp Research mines genetic material from rainforests, oceans, and hot springs to train machine learning models for drug discovery. The approach treats evolution as training data, leveraging billions of years of biological experimentation. CTO Phil Lorenz argues biology presents a fundamentally different problem for AI than language processing. Unlike text-based models, biological AI must bridge the gap between in-silico predictions and real-world molecular performance. The startup focuses on two applications: designing novel antibiotics to combat resistant infections, and developing tools for cell therapies. Basecamp's funding round demonstrates investor confidence in computational biology as a path to accelerated drug development. The company's thesis rests on a critical insight: high benchmark scores don't guarantee functional molecules. Successful AI in this space requires models that produce compounds with practical efficacy, not just theoretical promise.